Cargando…
Guillain-Barre Syndrome After COVID-19 Vaccination: A Secondary Analysis of Domestic Safety Data by the Japanese Government
Purpose The purpose of this study was to figure out the risk of Guillain-Barre syndrome (GBS) after coronavirus disease 2019 (COVID-19) vaccination, which has been reported as a rare adverse reaction. Methods Elucidating the characteristics, we performed a secondary analysis of the cases from Februa...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620737/ https://www.ncbi.nlm.nih.gov/pubmed/36337786 http://dx.doi.org/10.7759/cureus.30905 |
_version_ | 1784821388347965440 |
---|---|
author | Kaneda, Yudai Hashimoto, Takanao Kaneda, Uiri Higuchi, Yuka Murakami, Jun Inada, Masanari Senoo, Yuki Fujieda, Takeshi Murata, Yuki Tanimoto, Tetsuya |
author_facet | Kaneda, Yudai Hashimoto, Takanao Kaneda, Uiri Higuchi, Yuka Murakami, Jun Inada, Masanari Senoo, Yuki Fujieda, Takeshi Murata, Yuki Tanimoto, Tetsuya |
author_sort | Kaneda, Yudai |
collection | PubMed |
description | Purpose The purpose of this study was to figure out the risk of Guillain-Barre syndrome (GBS) after coronavirus disease 2019 (COVID-19) vaccination, which has been reported as a rare adverse reaction. Methods Elucidating the characteristics, we performed a secondary analysis of the cases from February 2020 through January 2022, based on the publicly available spontaneous adverse reaction reports in Japan. Results We identified 115 cases, and all were after messenger RNA (mRNA) vaccination. Of all the cases, 69 (60.0%) were female and 44 (38.2%) were older than 65 years old. Severe GBS was reported by 38 males (median age 61.5 years) and 51 females (median age 55 years). The median interval from vaccination to the onset of symptoms was eight days for males and four days for females. Sequelae were reported in 18 patients (7 males, median age 81 years; 11 females, median age 51 years), 11 of whom were older than 65 years old. The estimated incidence was about 0.0001% (0.000058% for the Pfizer vaccine and about 0.000046% for the Moderna vaccine, respectively). Conclusions Spontaneous reports would have various biases, the incidence of GBS after mRNA vaccination was as low as in other existing vaccination programs, and it is important not to interpret that risk expansively. |
format | Online Article Text |
id | pubmed-9620737 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-96207372022-11-04 Guillain-Barre Syndrome After COVID-19 Vaccination: A Secondary Analysis of Domestic Safety Data by the Japanese Government Kaneda, Yudai Hashimoto, Takanao Kaneda, Uiri Higuchi, Yuka Murakami, Jun Inada, Masanari Senoo, Yuki Fujieda, Takeshi Murata, Yuki Tanimoto, Tetsuya Cureus Neurology Purpose The purpose of this study was to figure out the risk of Guillain-Barre syndrome (GBS) after coronavirus disease 2019 (COVID-19) vaccination, which has been reported as a rare adverse reaction. Methods Elucidating the characteristics, we performed a secondary analysis of the cases from February 2020 through January 2022, based on the publicly available spontaneous adverse reaction reports in Japan. Results We identified 115 cases, and all were after messenger RNA (mRNA) vaccination. Of all the cases, 69 (60.0%) were female and 44 (38.2%) were older than 65 years old. Severe GBS was reported by 38 males (median age 61.5 years) and 51 females (median age 55 years). The median interval from vaccination to the onset of symptoms was eight days for males and four days for females. Sequelae were reported in 18 patients (7 males, median age 81 years; 11 females, median age 51 years), 11 of whom were older than 65 years old. The estimated incidence was about 0.0001% (0.000058% for the Pfizer vaccine and about 0.000046% for the Moderna vaccine, respectively). Conclusions Spontaneous reports would have various biases, the incidence of GBS after mRNA vaccination was as low as in other existing vaccination programs, and it is important not to interpret that risk expansively. Cureus 2022-10-31 /pmc/articles/PMC9620737/ /pubmed/36337786 http://dx.doi.org/10.7759/cureus.30905 Text en Copyright © 2022, Kaneda et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Neurology Kaneda, Yudai Hashimoto, Takanao Kaneda, Uiri Higuchi, Yuka Murakami, Jun Inada, Masanari Senoo, Yuki Fujieda, Takeshi Murata, Yuki Tanimoto, Tetsuya Guillain-Barre Syndrome After COVID-19 Vaccination: A Secondary Analysis of Domestic Safety Data by the Japanese Government |
title | Guillain-Barre Syndrome After COVID-19 Vaccination: A Secondary Analysis of Domestic Safety Data by the Japanese Government |
title_full | Guillain-Barre Syndrome After COVID-19 Vaccination: A Secondary Analysis of Domestic Safety Data by the Japanese Government |
title_fullStr | Guillain-Barre Syndrome After COVID-19 Vaccination: A Secondary Analysis of Domestic Safety Data by the Japanese Government |
title_full_unstemmed | Guillain-Barre Syndrome After COVID-19 Vaccination: A Secondary Analysis of Domestic Safety Data by the Japanese Government |
title_short | Guillain-Barre Syndrome After COVID-19 Vaccination: A Secondary Analysis of Domestic Safety Data by the Japanese Government |
title_sort | guillain-barre syndrome after covid-19 vaccination: a secondary analysis of domestic safety data by the japanese government |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620737/ https://www.ncbi.nlm.nih.gov/pubmed/36337786 http://dx.doi.org/10.7759/cureus.30905 |
work_keys_str_mv | AT kanedayudai guillainbarresyndromeaftercovid19vaccinationasecondaryanalysisofdomesticsafetydatabythejapanesegovernment AT hashimototakanao guillainbarresyndromeaftercovid19vaccinationasecondaryanalysisofdomesticsafetydatabythejapanesegovernment AT kanedauiri guillainbarresyndromeaftercovid19vaccinationasecondaryanalysisofdomesticsafetydatabythejapanesegovernment AT higuchiyuka guillainbarresyndromeaftercovid19vaccinationasecondaryanalysisofdomesticsafetydatabythejapanesegovernment AT murakamijun guillainbarresyndromeaftercovid19vaccinationasecondaryanalysisofdomesticsafetydatabythejapanesegovernment AT inadamasanari guillainbarresyndromeaftercovid19vaccinationasecondaryanalysisofdomesticsafetydatabythejapanesegovernment AT senooyuki guillainbarresyndromeaftercovid19vaccinationasecondaryanalysisofdomesticsafetydatabythejapanesegovernment AT fujiedatakeshi guillainbarresyndromeaftercovid19vaccinationasecondaryanalysisofdomesticsafetydatabythejapanesegovernment AT muratayuki guillainbarresyndromeaftercovid19vaccinationasecondaryanalysisofdomesticsafetydatabythejapanesegovernment AT tanimototetsuya guillainbarresyndromeaftercovid19vaccinationasecondaryanalysisofdomesticsafetydatabythejapanesegovernment |